Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
No open-market purchases or sales by Actuate Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Actuate Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Actuate Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Schmitt Daniel M | President, CEO and Director | 301,716 | Aug 14, 2026 | 3 |
| Thomson Todd S | Director, 10% Owner | 904,795Indirect | May 22, 2026 | 2 |
| Ronneberg Amy L | Director | – | May 22, 2026 | 1 |
| Huber Martin H. Jr. | Director | – | May 22, 2026 | 1 |
| Keyes Jason A | Director | – | May 22, 2026 | 1 |
| Fletcher Aaron G.L. | Director, 10% Owner | 196,428Indirect | May 22, 2026 | 1 |
| Sawhney Roger | Director | – | May 22, 2026 | 1 |
| Zabrowksi Dan | Director | – | May 22, 2026 | 1 |
| Lytle Paul J | Chief Financial Officer | – | Apr 1, 2026 | 1 |
| Mazar Andrew Paul | Chief Operating Officer | – | Apr 1, 2026 | 1 |
| Kairos Venture Partners II, L.P. | Director, 10% Owner | 904,795Indirect | Jan 7, 2026 | 1 |
| BP Directors, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios Clinical Opportunity Fund, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios Equity COF, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios 2024 Co-Invest, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund I, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund I QP, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund II, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund II QP, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund II NT, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Cavu Management, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Cavu Advisors, LLC | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios Equity Partners II, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios Equity Partners, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Kreis Leslie W. | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Actuate Co-Invest I, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund III NT, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund III QP, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Fund III, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Advisors GP, LLC | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Capital Management, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Actuate Co-Invest II, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| BIOS Equity Partners III, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Bios Actuate Co-Invest III, LP | Director, 10% Owner | 196,428Indirect | Jun 30, 2025 | 0 |
| Kairos Venture Opportunities I, L.P. | Director, Other: 5.3% Owner | 1,184,795Indirect | Aug 16, 2024 | 0 |
| Kairos SPV Fund LLC | Director, Other: 2% Owner | 1,184,795Indirect | Aug 16, 2024 | 0 |
| Kairos-Actuate SPV, L.P. | Director, Other: 1.5% Owner | 1,184,795Indirect | Aug 16, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 (view filing)12:45 PM ET | Jan 5 | 2 days | Thomson Todd S and 1 otherDirector, 10% Owner | SSale | −280.0K | $5.80 | −$1.62M | −23.6%904.8K after | |
| Jun 30, 2025 (view filing)1:03 PM ET | Jun 27 | 3 days | BP Directors, LP and 3 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | Duplicate filing |
| Jun 30, 2025 (view filing)1:03 PM ET | Jun 27 | 3 days | BP Directors, LP and 3 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | DerivativeDuplicate filing |
| Jun 30, 2025 (view filing)1:02 PM ET | Jun 27 | 3 days | BIOS Fund I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | Duplicate filing |
| Jun 30, 2025 (view filing)1:02 PM ET | Jun 27 | 3 days | BIOS Fund I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | DerivativeDuplicate filing |
| Jun 30, 2025 (view filing)1:01 PM ET | Jun 27 | 3 days | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $7.00 | +$500.0K | +57.1%196.4K after | |
| Jun 30, 2025 (view filing)1:01 PM ET | Jun 27 | 3 days | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | PPurchase | +71.4K | $0.00 | $0 | –71.4K after | Derivative |
| Aug 20, 2024 (view filing)8:46 PM ET | Aug 14 | 6 days | BP Directors, LP and 2 othersDirector, 10% Owner | SSale | −25.0K | $8.00 | −$200.0K | −16.0%131.2K after | Amended3 lotsDuplicate filing |
| Aug 20, 2024 (view filing)8:46 PM ET | Aug 14 | 6 days | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | SSale | −25.0K | $8.00 | −$200.0K | −16.0%131.2K after | Amended3 lotsDuplicate filing |
| Aug 20, 2024 (view filing)8:45 PM ET | Aug 14 | 6 days | BIOS Fund I, LP and 9 othersDirector, 10% Owner | SSale | −25.0K | $8.00 | −$200.0K | −16.0%131.2K after | Amended3 lots |
| Aug 16, 2024 (view filing)9:12 PM ET | Aug 14 | 2 days | Thomson Todd S and 4 othersDirector, Other: 16.4% Owner | SSale | −18.8K | $8.00 | −$150.0K | −1.6%1.18M after | |
| Aug 14, 2024 (view filing)8:54 PM ET | Aug 14 | Same day | BP Directors, LP and 2 othersDirector, 10% Owner | PPurchase | +500.0K | $8.00 | +$4.00M | New position125.0K after | 2 lotsDuplicate filing |
| Aug 14, 2024 (view filing)8:54 PM ET | Aug 14 | Same day | BP Directors, LP and 2 othersDirector, 10% Owner | SSale | −25.0K | $9.00 | −$225.0K | −16.0%131.2K after | 3 lotsDuplicate filing |
| Aug 14, 2024 (view filing)8:49 PM ET | Aug 14 | Same day | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | PPurchase | +500.0K | $8.00 | +$4.00M | New position125.0K after | 2 lotsDuplicate filing |
| Aug 14, 2024 (view filing)8:49 PM ET | Aug 14 | Same day | BIOS Actuate Co-Invest I, LP and 9 othersDirector, 10% Owner | SSale | −25.0K | $9.00 | −$225.0K | −16.0%131.2K after | 3 lotsDuplicate filing |
| Aug 14, 2024 (view filing)8:44 PM ET | Aug 14 | Same day | BIOS Fund I, LP and 9 othersDirector, 10% Owner | PPurchase | +500.0K | $8.00 | +$4.00M | New position125.0K after | 2 lots |
| Aug 14, 2024 (view filing)8:44 PM ET | Aug 14 | Same day | BIOS Fund I, LP and 9 othersDirector, 10% Owner | SSale | −25.0K | $9.00 | −$225.0K | −16.0%131.2K after | 3 lots |